Publication date: May 20, 2022
This Phase 1b/2a study will assess the efficacy, safety, and pharmacodynamics of CyPep-1 when administered directly into measurable tumor lesions in combination with the anti-PD-1 antibody pembrolizumab. Additionally, the study will assess anti-tumor effects of CyPep-1 on injected lesions and non-injected target lesions identified at baseline, as well as local and systemic immunological effects of CyPep-1 in combination with pembrolizumab.
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | bundle branch block |
| disease | MESH | atrial fibrillation |
| disease | MESH | Torsade de Pointes |
| disease | MESH | Brugada syndrome |
| disease | MESH | short QT syndrome |
| disease | MESH | carcinomatous meningitis |
| disease | MESH | Castleman Disease |
| disease | MESH | Kaposi sarcoma |
| disease | MESH | interstitial lung disease |
| disease | MESH | pneumonitis |
| disease | MESH | hypothyroidism |
| disease | MESH | hypersensitivity |
| drug | DRUGBANK | Heparin |
| drug | DRUGBANK | Prothrombin |
| drug | DRUGBANK | Prednisone |
| disease | MESH | pituitary insufficiency |
| disease | MESH | skin cancer |
| disease | MESH | autoimmune disease |
| pathway | KEGG | Melanoma |
| disease | MESH | melanoma |
| disease | MESH | carcinomas |
| disease | MESH | carcinoma in situ |
| disease | MESH | metastasis |
| drug | DRUGBANK | Denosumab |
| pathway | REACTOME | SARS-CoV-2 Infection |
| disease | MESH | infection |
| disease | MESH | COVID-19 |
| disease | MESH | amenorrhea |
| disease | MESH | biopsy |
| disease | MESH | Cancers |
| drug | DRUGBANK | Pembrolizumab |